CSF1R and nonpapillary renal cell carcinoma: There, TGFBI (5q31) was reported to be amplified in 70% of ccRCC cases (7/10) with 5q23.2–q34 gain [54] and CSF1R (5q32) to be upregulated in 30% of tumours (3/10) [55].